Metastatic Colorectal Cancer: Treatment Challenges, Progress, and Advice With Chiara Cremolini, MD

Colorectal cancer is the third leading cause of cancer death and the fourth most common diagnosed cancer in the world. Often, this disease is left undiagnosed until it reaches an advanced stage. Unfortunately, late-stage metastatic colorectal cancer has a poor prognosis with a 5-year survival rate of only 12%. In an interview with i3 Health, Chiara Cremolini, MD, provides insights on the challenges of treating patients with metastatic colorectal cancer, explains how metastatic colorectal cancer ...
Continue reading

FOLFOXIRI Efficacy in Metastatic Colorectal Cancer: Chiara Cremolini, MD

Results of TRIBE2, a phase 3 trial (NCT02339116), show that the triplet treatment FOLFOXIRI (fluorouracil/leucovorin/oxaliplatin/irinotecan) plus bevacizumab is more effective at treating patients with metastatic colorectal cancer than FOLFIRI (irinotecan/leucovorin/fluorouracil) plus bevacizumab. In an interview with i3 Health, Chiara Cremolini, MD, lead researcher of this study, provides insights on the results of this trial as well as how the future of treatment for metastatic colorectal canc...
Continue reading

FOLFOXIRI Combo Effective for Metastatic Colorectal Cancer?

According to the results of TRIBE2, a phase 3 trial (NCT02339116), the triplet treatment FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) in combination with bevacizumab has been shown to be more effective in treating patients with metastatic colorectal cancer before and after disease progression compared with sequential administration of chemotherapy doublets plus bevacizumab. Patients aged 18 to 75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 2...
Continue reading

Continued Induction, Maintenance, or Observation: Which Is Most Effective for Metastatic Colorectal Cancer?

For patients with metastatic colorectal cancer, the standard treatment is induction combination chemotherapy with a targeted agent. However, clinical trials that involved patients either continuing cytotoxic therapy until disease progression or observation have shown inconsistent efficacy results. To close this gap, a systematic review and network meta-analysis was conducted and revealed that continued induction therapy until progression offered no survival benefit compared with maintenance fluo...
Continue reading

​Safe Dose of Regorafenib For Metastatic Colorectal Cancer

In patients with refractory metastatic colorectal cancer, regorafenib (Stivarga®, Bayer) provides a good overall survival benefit. Unfortunately, it also causes a lot of side effects, such as infection, severe bleeding, tears in the stomach or intestinal wall, hand-foot skin reaction, severe skin rash, high blood pressure, decreased blood flow to the heart, heart attack, reversible posterior leukoencephalopathy syndrome, and wound healing problems, all of which limit its usefulness. In order to ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.